secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2025-07-22T23:59:59+00:00
Accession:  0001193125-25-162233
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus closes $350M acquisition of Life Molecular Imaging; names Dr. Dinkelborg as Head of R&D
--------------------------------------------------------------------------------

- Completed acquisition of Life Molecular for $350M cash after adjustments, gaining Alzheimer's PET agent Neuraceq.
- Appointed Dr. Ludger Dinkelborg, former Life Molecular CEO, as Head of R&D effective Aug 1, 2025.
- Transaction adds commercial infrastructure, R&D capabilities, and international footprint for Alzheimer's radiodiagnostics.
- Dinkelborg will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/0001193125-25-162233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/d89717d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-162233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer